Full-Time

Master Production Planner Associate Director

Gilead Sciences

Gilead Sciences

10,001+ employees

Biopharmaceutical firm developing HIV/AIDS therapies

Compensation Overview

$182.1k - $235.6k/yr

+ Discretionary Annual Bonus + Discretionary Stock-Based Long-Term Incentives

Company Historically Provides H1B Sponsorship

San Mateo, CA, USA

Hybrid

Hybrid work setup; some on-site days in Foster City, CA.

Bachelor's, Master's, MBA, PhD

Category
Operations & Logistics (1)
Required Skills
SAP Products

Get referred to Gilead Sciences

See people who can refer or advise you

Requirements
  • Bachelor’s degree in Supply Chain, Operations, Engineering, Life Sciences, or related field with 10+ years of relevant experience OR Masters degree in Supply Chain, Operations, Engineering, Life Sciences, or related field with 8+ years of relevant experience OR PhD in Supply Chain, Operations, Engineering, Life Sciences, or related field with 5+ years of relevant experience
  • Supply chain planning experience, with strong exposure to network and site planning required
  • Deep understanding of GMP operations, internal and external manufacturing, batch‑based production, and global distribution flows
  • Proficiency with ERP and advanced planning systems (SAP, IBP, OMP, Kinaxis)
  • Strong influencing skills across global, matrixed organizations
Responsibilities
  • Translate global demand signals, inventory policies, and supply network strategies into feasible, detailed site‑level production schedules
  • Lead integration between Global Network Planning and Site Planning teams to ensure alignment on feasibility, constraints, and assumptions
  • Reconcile the Global Supply Plan (GSP) with Site Rough‑Cut Capacity Plans (RCCP), resolving discrepancies prior to execution
  • Own and govern the 24‑month master production schedule for DS, DP, and FG across internal and external manufacturing nodes
  • Build batch sequences, production cycles, campaign structures, and capacity allocations
  • Ensure MPS stability within the 4‑month frozen window while enabling appropriate agility outside it
  • Lead scenario modeling and recommend adjustments in response to supply risks, capacity shifts, regulatory changes, and demand variability
  • Owning the 6–24‑month unconstrained planning horizon, translating global strategies into forward‑looking production plans
  • Conducting advanced long‑range capacity modeling to identify constraints, maintenance windows, QC load, labor availability, and network balancing needs
  • Running structured scenario analyses for launch acceleration, demand shifts, supply disruptions, regulatory changes, and market expansions
  • Driving early alignment between Global Network Planners and Site Planners to validate assumptions and address issues before the frozen zone
  • Partnering with Procurement and Materials teams to confirm long‑lead material readiness and supplier feasibility
  • Validating feasibility for lifecycle initiatives such as tech transfers, new SKUs, artwork/label updates, and new market entries
  • Leading long‑range planning forums with Global Planning, Site Planning, External Manufacturing, Quality, Regulatory, and Technical Operations
  • Identifying long‑range risks and establishing mitigation strategies ahead of the 4‑month window
  • Maintain governance for all plan changes within the 4‑month frozen window
  • Ensure major planning decisions (campaign timing, capacity adjustments, material commitments) are resolved before entering the frozen horizon
  • Protect execution stability by minimizing late changes and deviations within the fixed window
  • Manage any required exceptions through established supply governance forums
  • Serve as the central planning interface to internal manufacturing sites
  • Partner closely with internal Site Supply Chain, Manufacturing Operations, and Master Scheduling teams to confirm production feasibility, capacity availability, and alignment with maintenance, labor, and equipment constraints
  • Coordinate with internal network governance to ensure synchronized DS, DP, and FG flows across internal nodes
  • Monitor schedule adherence at internal sites, capturing deviations, understanding drivers, and ensuring timely corrective actions
  • Provide internal manufacturing sites with 6–24‑month long‑range visibility to support staffing plans, capital/asset planning, material readiness, and QA/QC workload forecasting
  • Serve as the central planning interface to the Global External Manufacturing (GEM) organization
  • Partner with GEM to validate slot reservations, campaign timing, yield expectations, testing sequences, and release timelines across the external network
  • Collaborate with GEM to maintain synchronized production calendars and ensure visibility across DS, DP, and FG flows
  • Monitor schedule adherence and network performance through GEM, supporting proactive escalation and issue resolution
  • Provide GEM with 6–24‑month long‑range visibility to enable proactive contracting, supplier readiness, and risk mitigation
  • Align MPS with material availability, safety stock policies, and procurement strategies
  • Support lifecycle readiness including artwork changes, regulatory updates, tech transfers, and market expansions
  • Maintain appropriate inventory levels to support service targets while minimizing E&O exposure and working capital
  • Track and report KPIs including MPS attainment, Schedule adherence across internal and external nodes, Capacity utilization, Supply reliability / OTIF, Inventory health
  • Ensure adherence to Plan Stability and Performance‑to‑Plan metrics, and manage any exceptions diligently through established governance processes
  • Partner with Digital/IT teams to improve planning tool capabilities (SAP, IBP, OMP, Kinaxis) and data quality
  • Lead continuous improvement initiatives to enhance planning discipline, cycle time reduction, and cross‑functional integration
  • Create Inclusion - knowing the business value of diverse teams, modeling inclusion, and embedding the value of diversity in the way they manage their teams
  • Develop Talent - understand the skills, experience, aspirations and potential of their employees and coach them on current performance and future potential
  • Empower Teams - connect the team to the organization by aligning goals, purpose, and organizational objectives, and holding them to account
Desired Qualifications
  • APICS CPIM/CSCP certification or MBA (advanced degree)
  • Experience with commercial biologics or sterile injectables
  • Experience with S&OP/S&OE processes and supply governance frameworks

Gilead Sciences discovers, develops, and markets medicines to treat HIV/AIDS, liver diseases, cancer, inflammatory and respiratory diseases, and cardiovascular conditions. Its products reach patients globally after regulatory approval, sold through doctors, hospitals, and pharmacies. The company relies on a large, diverse R&D pipeline and strategic partnerships to expand its therapies and reach, including collaborations like SAP Ariba to improve sourcing. Its goal is to improve health equity by expanding access to medicines and promoting sustainable healthcare practices worldwide.

Company Size

10,001+

Company Stage

IPO

Headquarters

Foster City, California

Founded

1987

Get referred to Gilead Sciences

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Q2 2026 revenue rose 10% to $7.8 billion, led by HIV and Trodelvy.
  • Yeztugo PrEP sales surpassed $1 billion in Q2 2026, proving durable prevention demand.
  • California Supreme Court dismissed 23,000 HIV claims on August 3, removing litigation overhang.

What critics are saying

  • Biktarvy concentration exposes Gilead if ViiV or generics erode HIV share before 2036.
  • Veklury sales plunged 81% in Q2 2026, exposing dependence on shrinking pandemic revenue.
  • Anito-cel’s December 23, 2026 PDUFA is binary; rejection would weaken Gilead’s oncology expansion.

What makes Gilead Sciences unique

  • Biktarvy remains protected until April 1, 2036, anchoring Gilead’s HIV cash engine.
  • Gilead leads long-acting HIV prevention with Yeztugo, now available in 10 priority countries.
  • Its oncology mix combines Trodelvy, Yescarta, Tecartus, and anito-cel’s December 2026 launch.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Paid family time off and paid parental time off

Generous 401(k) contribution matching

Comprehensive medical plans that cover both physical and mental healthcare

Global Wellbeing Reimbursement

Time Off

Global Volunteer Day

Giving Together Program

Employee Support Programs

Flexible Work Options

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

0%

2 year growth

0%
Ticker Report
Aug 18th, 2026
MidFirst Bank Makes New $810,000 Investment in Gilead Sciences, Inc. $GILD

MidFirst Bank acquired a new stake in Gilead Sciences, Inc. (NASDAQ:GILD – Free Report) in the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The firm acquired 6,414 shares of the biopharmaceutical company’s stock, valued at approximately $810,000. A number of other hedge funds and other institutional investors […]

Yahoo Finance
Aug 16th, 2026
Gilead Sciences down 11.3% in six months as revenue growth disappoints at 2.7% CAGR

Gilead Sciences' shares have fallen 11.3% to $137.77 over the past six months, contrasting with the S&P 500's 13.1% gain. The biopharmaceutical company has shown disappointing long-term performance, with revenue growing at just 2.7% annually over five years. The company's profitability metrics have deteriorated significantly. Its adjusted operating margin decreased by 34.2 percentage points over the past five years, landing at 9.7% for the trailing 12 months. Earnings per share declined by 15.4% annually during the same period, indicating reduced profitability as the company expanded. Despite trading at a relatively fair valuation of 14.9× forward price-to-earnings ratio, analysts suggest limited upside potential compared to downside risk.

Yahoo Finance
Aug 13th, 2026
Gilead Sciences beats Q2 estimates with $7.8B revenue as PrEP sales top $1B for first time

Gilead Sciences reported strong Q2 results, with revenue of $7.80 billion, beating analyst estimates of $7.35 billion. The 10.2% year-on-year growth was driven by its HIV franchise, particularly Biktarvy and the PrEP segment, alongside advances in oncology and liver disease treatments. CEO Daniel O'Day highlighted that quarterly PrEP sales doubled year-on-year, exceeding $1 billion for the first time. New product launches, including Trodelvy in breast cancer and Livdelzi in liver disease, contributed to the results. The company raised its full-year revenue guidance to $30.25 billion at the midpoint and increased adjusted EPS guidance by 44.1%. During the earnings call, analysts questioned management about prescription trends, product strategies, revenue diversification, regulatory interactions, and the impact of US insurance changes on Biktarvy's growth.

Ochre Digi Media Pvt. Ltd.
Aug 12th, 2026
Nucleai advances ai-powered Tissue Intelligence through large-scale oncology ADC collaboration.

Nucleai advances ai-powered Tissue Intelligence through large-scale oncology ADC collaboration. Wednesday, August 12, 2026 Nucleai, a leader in AI-powered Tissue Intelligence, which integrates multimodal tissue image analysis with clinical data to deliver translational insights, today announced an ongoing translational research collaboration with Gilead Sciences supporting its global antibody-drug conjugate (ADC) clinical development programs. As oncology drug development increasingly depends on understanding tissue biology in its spatial context, AI-powered tissue analytics are becoming an essential component of biomarker discovery and translational research. Pharmaceutical companies are increasingly adopting approaches that integrate tissue architecture, biomarker expression, and clinical outcomes to accelerate therapeutic development. Nucleai's AI-native platform transforms routine pathology images into quantitative biological insights that accelerate biomarker discovery and support evidence-driven development decisions. As part of its collaboration with Gilead, Nucleai has analyzed a large dataset of hematoxylin and eosin (H&E) and immunohistochemistry (IHC) whole-slide images across several clinical studies spanning multiple oncology indications, supporting Gilead's global ADC clinical development programs through advanced AI-driven tissue analytics integrated with clinical outcomes. The collaboration has generated novel biological insights and candidate spatial biomarkers for future scientific presentations and publications. The collaboration demonstrates how AI-powered Tissue Intelligence can standardize biomarker analyses while connecting tissue biology to clinical outcomes, creating a scalable foundation for translational research, biomarker development, and precision medicine. "Precision oncology is entering a new phase, where understanding tissue architecture is becoming just as important as understanding molecular alterations," said Avi Veidman, Chief Executive Officer of Nucleai. "Tissue Intelligence is becoming a foundational capability for precision medicine, helping identify the patients most likely to benefit while enabling pharmaceutical companies to translate tissue biology into reproducible biomarkers that improve the speed and success of oncology drug development." Unlike traditional image analysis approaches, Nucleai's AI-native platform integrates computational pathology, spatial biology, clinical outcomes, and multimodal data into a unified framework. This enables standardized biomarker assessment from preclinical research through late-stage clinical development while revealing mechanisms of response, resistance, and disease progression. The ongoing collaboration with Gilead and other leading pharmaceutical companies reflects growing industry recognition that AI-powered tissue analytics strengthen biomarker development and precision medicine across oncology portfolios. As target expression alone proves insufficient to explain ADC response, Nucleai's Tissue Intelligence platform integrates protein expression with tissue architecture, tumor heterogeneity, and microenvironmental context to better characterize the biological drivers of therapeutic efficacy. "Scale and reproducibility are becoming essential requirements for biomarker development," said Dr. Ken Bloom, Head of Pathology, Nucleai. "Our platform enables standardized spatial analyses across thousands of clinical samples while directly linking tissue biology to patient outcomes, generating evidence that can support translational research, biomarker qualification, and future companion diagnostic strategies." Nucleai continues to expand collaborations with leading pharmaceutical companies to advance biomarker discovery, translational medicine, companion diagnostic development, and AI-powered Tissue Intelligence across the oncology development lifecycle. About Nucleai Nucleai is a leader in AI-powered Tissue Intelligence, transforming pathology images into clinically actionable insights for pharmaceutical companies developing the next generation of precision medicines. By integrating computational pathology, spatial biology, multi-omics, and clinical data, Nucleai enables biomarker discovery, translational research, companion diagnostic development, and enterprise-scale AI-powered tissue analytics across the oncology development lifecycle. Contacts Media Contact Patrick Schmidt, Consort Partners [email protected]

Yahoo Finance
Aug 8th, 2026
Gilead raises 2026 outlook on HIV and PrEP strength, targets $30B in sales

Gilead Sciences reported second-quarter 2026 results that exceeded expectations, with revenues of $7.8 billion, up 10% year over year, and a non-GAAP loss per share of $6.75 beating consensus estimates. The company raised its full-year guidance for product sales excluding Veklury to $29.8 billion to $30.1 billion, an increase of $350 million at the midpoint. HIV sales drove growth, rising 12% in the quarter. Quarterly PrEP sales surpassed $1 billion for the first time, putting the prevention business at a $4 billion annual run rate. Gilead now expects full-year HIV sales to increase 9% to 10%, up from its prior 8% outlook. Biktarvy generated $3.8 billion in sales, whilst newer product Yeztugo delivered $232 million. The company maintained its approximately $1 billion full-year Yeztugo sales target, with more than 70% of users returning for reinjection at six months.